Novavax Management
Management criteria checks 3/4
Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 3.08 years. total yearly compensation is $5.09M, comprised of 14.8% salary and 85.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth CHF1.16M. The average tenure of the management team and the board of directors is 3 years and 5.2 years respectively.
Key information
John Jacobs
Chief executive officer
US$5.1m
Total compensation
| CEO salary percentage | 14.79% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | US$342m |
| Jun 30 2025 | n/a | n/a | US$423m |
| Mar 31 2025 | n/a | n/a | US$479m |
| Dec 31 2024 | US$5m | US$753k | -US$187m |
| Sep 30 2024 | n/a | n/a | -US$285m |
| Jun 30 2024 | n/a | n/a | -US$294m |
| Mar 31 2024 | n/a | n/a | -US$399m |
| Dec 31 2023 | US$7m | US$663k | -US$545m |
Compensation vs Market: John's total compensation ($USD5.09M) is above average for companies of similar size in the Swiss market ($USD1.60M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Jacobs (58 yo)
Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$5.09m | 0.11% CHF 1.2m | |
| Executive VP | 4.5yrs | US$1.83m | 0.044% CHF 458.2k | |
| Executive VP | 2.2yrs | US$1.06m | 0.038% CHF 391.2k | |
| Executive VP & Chief Strategy Officer | 3yrs | US$1.64m | 0.035% CHF 367.7k | |
| Executive VP & COO | 3.1yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP | no data | no data | no data | |
| Associate Director of Investor & Public Relations | 7.8yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | 2.6yrs | no data | no data | |
| Executive VP | 4.1yrs | no data | no data | |
| Executive VP & Chief Regulatory Officer | less than a year | no data | no data | |
| Senior VP & Chief Medical Officer | 1.3yrs | no data | no data |
Experienced Management: NVAX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.1yrs | US$5.09m | 0.11% CHF 1.2m | |
| Independent Director | 5.7yrs | US$468.61k | 0.037% CHF 389.5k | |
| Independent Director | 16.1yrs | US$470.61k | 0.033% CHF 347.6k | |
| Independent Chairperson | 5.2yrs | US$466.08k | 0.016% CHF 163.7k | |
| Independent Director | 5.3yrs | US$453.43k | 0.018% CHF 184.3k | |
| Independent Director | 7.3yrs | US$456.11k | 0.015% CHF 161.1k | |
| Independent Director | 3.3yrs | US$476.43k | 0.018% CHF 182.2k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.1yrs | no data | no data |
Experienced Board: NVAX's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 05:34 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novavax, Inc. is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| David Lebowitz | Brean Capital (formerly Janney Montgomery) |
| Mayank Mamtani | B. Riley Securities, Inc. |